

The logo for PHARMAC (Te Pātaka Whaioranga) is a white circle containing the text 'PHARMAC' in a large, bold, sans-serif font, with 'TE PĀTAKA WHAIORANGA' in a smaller, all-caps, sans-serif font below it. The background of the entire page is a grey-to-white gradient with a large, intricate, white geometric pattern of concentric, curved lines that resemble a stylized spiral or a complex maze.

PHARMAC  
TE PĀTAKA WHAIORANGA

Pharmaceutical Management Agency  
New Zealand  
Pharmaceutical Schedule

# Update

November 2021

# Contents

|   |    |
|---|----|
| Summary of Pharmac decisions effective 1 November 2021 .....  | 3  |
| Tender News .....   | 5  |
| Looking Forward .....   | 6  |
| Sole Subsidised Supply (SSS) or Principal Supply Status (PSS) Products<br>– Cumulative to November 2021 ..... | 7  |
| New Listings.....   | 19 |
| Changes to Restrictions, Chemical Names and Presentations .....   | 21 |
| Changes to Subsidy and Manufacturer’s Price.....  | 24 |
| Delisted Items .....  | 25 |
| Items to be Delisted .....  | 26 |
| Index.....  | 28 |

# Summary of Pharmac decisions

EFFECTIVE 1 NOVEMBER 2021

## **New listings (page 19)**

- Pyridoxine hydrochloride (Pyridoxine multichem) tab 50 mg – no more than 100 mg per dose and only on a prescription
- Folic acid (Folic Acid multichem) tab 0.8 mg
- Prazosin (Apo-Prazosin S29) tab 1 mg, 2 mg and 5 mg – section 29 and wastage claimable
- Methyldopa (Methyldopa Mylan) tab 250 mg (Pharmacode 2603934)
- Aqueous cream (GEM Aqueous Cream) crm, 500 g
- Ketoconazole (Sebizole) shampoo 2%, 100 ml OP (Pharmacode 361410) – maximum of 100 ml per prescription and only on a prescription
- Darunavir (Darunavir Mylan) tab 400 mg (Pharmacode 2591286) – Special Authority – Retail pharmacy
- Cinacalcet (Cinacalcet Devatis) tab 30 mg and 60 mg – Special Authority – Retail pharmacy and wastage claimable
- Entacapone (Comtan) tab 200 mg
- Amisulpride (Sulprix) tab 100 mg (Pharmacode 2609401)
- Melatonin (Vigisom) tab modified-release 2 mg – Special Authority – Retail pharmacy and no more than 5 tab per day
- Bortezomib (Bortezomib Juno) inj 2.5 mg vial – PCT only – Specialist – Special Authority, section 29

## **Changes to restrictions (pages 21-23)**

- Prazosin (Apo-Prazosin and Apo-Prazosin S29) tab 1 mg, 2 mg and 5 mg – removal of subsidy endorsement
- Testosterone undecanoate (Andriol Testocaps) cap 40 mg – addition of subsidy by endorsement
- Oestradiol valerate (Progynova) tab 2 mg – removal of stat dispensing
- Clarithromycin tab 250 mg (Apo-Clarithromycin and Klacid) and grans for oral liq 250 mg per 5 ml (Klacid) – amended restriction criteria
- Infliximab inj 100 mg (Remicade) and inj 1 mg for ECP (Baxter) – amended Special Authority criteria
- Rituximab (Riximyo) inj 100 mg per 10 ml vial and inj 500 mg per 50 ml vial (Riximyo) and inj 1 mg for ECP (Baxter (Riximyo)) – amended Special Authority criteria
- Secukinumab (Cosentyx) inj 150 mg per ml, 1 ml prefilled syringe – amended Special Authority criteria

## Summary of Pharmac decisions – effective 1 November 2021 (continued)

### **Increased subsidy (page 24)**

- Zinc and castor oil (Boucher) oint, 500 g
- Gentamicin sulphate (DBL Gentamicin) inj 10 mg per ml, 1 ml ampoule
- Ibuprofen (Ethics) oral liq 20 mg per ml, 200 ml
- Fentanyl (Boucher and Muir) inj 50 mcg per ml, 2 ml ampoule
- Primidone (Apo-Primidone) tab 250 mg
- Phenobarbitone sodium (Max Health) inj 200 mcg per ml, 1 ml ampoule
- Octreotide (Octreotide GH) inj 500 mcg per ml, 1 ml ampoule
- Beclomethasone dipropionate (Qvar) aerosol inhaler, 50 mcg per dose and aerosol inhaler, 100 mcg per dose, 200 dose OP
- Bimatoprost (Bimatoprost Multichem) eye drops 0.03%, 3 ml OP

### **Decreased subsidy (page 24)**

- Rivastigmine (Generic Partners) patch 9.5 mg per 24 hour

# Tender News

## Sole Subsidised Supply (SSS) or Principal Supply Status (PSS) changes – effective 1 December 2021

| Chemical Name                                | Presentation; Pack size   | PSS/ SSS | PSS/SSS brand (and supplier)                     |
|--|---|----------|--|
| Acarbose                                     | Tab 50 mg; 90 tab<br>Tab 100 mg; 90 tab   | PSS      | Accarb (Mylan)                                   |
| Aprepitant                                   | Cap 2 x 80 mg and 1 x 125 mg; 3 OP  | PSS      | Emend Tripack (MSD)                              |
| Atorvastatin                                 | Tab 10 mg; 500 tab<br>Tab 20 mg; 500 tab<br>Tab 40 mg; 500 tab<br>Tab 80 mg; 500 tab                        | PSS      | Lorstat (Mylan)                                  |
| Azithromycin                                 | Tab 500 mg; 2 tab   | SSS      | Zithromax (Pfizer)                               |
| Baclofen                                     | Inj 2 mg per ml; 5 ml ampoule; 5 inj  | PSS      | Medsurge (Medsurge)                              |
| Betamethasone dipropionate with calcipotriol | Oint 500 mcg with calcipotriol 50 mcg per g; 30 g OP<br>Gel 500 mcg with calcipotriol 50 mcg per g; 60 g OP | PSS      | Daivobet (LEO Pharma)                            |
| Bisacodyl                                    | Suppos 10 mg; 10 tab  | PSS      | Lax-suppositories (AFT)                          |
| Bosentan                                     | Tab 62.5 mg; 60 tab<br>Tab 125 mg; 60 tab   | PSS      | Bosentan Dr Reddy's (Dr Reddy's)                 |
| Candesartan cilexetil                        | Tab 4 mg; 90 tab<br>Tab 8 mg; 90 tab<br>Tab 16 mg; 90 tab<br>Tab 32 mg; 90 tab                              | PSS      | Candestar (Mylan)                                |
| Cyclizine hydrochloride                      | Tab 50 mg; 10 tab   | PSS      | Nausicalm (AFT)                                  |
| Crotamiton                                   | Crn 10%; 20 g OP  | PSS      | Itch-soothe (AFT)                                |
| Dorzolamide with timolol                     | Eye drops 2% with timolol 0.5%; 5 ml OP   | PSS      | Dortimopt (Mylan)                                |
| Filgrastim                                   | Inj 300 mcg per 0.5 ml; 10 inj<br>Inj 480 mcg per 0.5 ml; 10 inj  | PSS      | Nivestim (Pfizer)                                |
| Fluticasone propionate                       | Metered aqueous nasal spray, 50 mcg per dose; 120 dose OP   | PSS      | Flixonase Hayfever & Allergy (GSK)               |
| Fluorouracil sodium                          | Crn 5%; 20 g OP   | PSS      | Efudix (Inova)                                   |
| Folic Acid                                   | Tab 5 mg; 100 tab   | SSS      | Folic Acid Mylan (Mylan)                         |
| Hydrocortisone butyrate                      | Oint 0.1%; 100 g OP<br>Scalp lotn 0.1%; 100 ml OP<br>Milky emul 0.1%; 100 ml OP                             | PSS      | Locoid (LEO Pharma)<br>Locoid Crelo (LEO Pharma) |
| Hydrocortisone with miconazole               | Crn 1% with miconazole 2%; 15 g OP  | PSS      | Micreme H (Mylan)                                |
| Lansoprazole                                 | Cap 15 mg; 100 cap<br>Cap 30 mg; 100 cap  | PSS      | Lanzol Relief (Mylan)                            |
| Lorazepam                                    | Tab 1 mg; 250 tab<br>Tab 2.5 mg; 100 tab  | PSS      | Ativan (Aspen Pharma)                            |

**Sole Subsidised Supply (SSS) or Principal Supply Status (PSS) changes**  
**– effective 1 December 2021 (continued)**

| Chemical Name                     | Presentation; Pack size  | PSS/ SSS | PSS/SSS brand (and supplier)             |
|-----------------------------------|--|----------|--|
| Miconazole                        | Oral gel 20 mg per g; 40 g OP  | PSS      | Decozol (AFT)                            |
| Ornidazole                        | Tab 500 mg; 10 tab   | PSS      | Arrow-Ornidazole (Teva)                  |
| Oxycodone hydrochloride           | Cap immediate-release 5 mg; 20 cap<br>Cap immediate-release 10 mg; 20 cap<br>Cap immediate-release 20 mg; 20 cap | PSS      | Oxynorm<br>(MundiPharma New Zealand Ltd) |
| Paracetamol                       | Tab 500 mg – bottle tab; 1,000 tab   | SSS      | Noumed Paracetamol (Noumed) *            |
| Prednisolone                      | Oral liq 5 mg per ml; 30 ml OP   | PSS      | Redipred (Aspen Pharma)                  |
| Riluzole                          | Tab 50 mg; 56 tab  | PSS      | Rilutek (Sanofi-Aventis)                 |
| Sodium fusidate<br>[Fusidic acid] | Crn 2%; 5 g OP<br>Oint 2%; 5 g OP  | PSS      | Foban (AFT)                              |
| Solifenacin succinate             | Tab 5 mg; 30 tab<br>Tab 10 mg; 30 tab  | PSS      | Solifenacin Mylan (Mylan)                |
| Travoprost                        | Eye drops 0.004%; 2.5 ml OP  | PSS      | Travatan (Novartis)                      |
| Valganciclovir                    | Tab 450 mg; 60 tab   | PSS      | Valganciclovir Mylan (Mylan)             |
| Zoledronic acid                   | Inj 4 mg per 5 ml, vial; 1 vial  | PSS      | Zoledronic Acid Mylan (Mylan)            |

\*Noumed Paracetamol tab 500 mg – bottle pack Sole supply status to be delayed to 1 February 2022.

## Looking Forward

*This section is designed to alert both pharmacists and prescribers to possible future changes to the Pharmaceutical Schedule. It may also assist pharmacists, distributors and wholesalers to manage stock levels.*

### Decisions for implementation 1 December 2021

- Folic acid tab 5 mg – addition of Brand Switch Fee
- Rosuvastatin (Mylan Rosuvastatin) tab 5 mg, 10 mg, 20 mg and 40 mg  
– new listing

## Sole Subsidised Supply (SSS) or Principal Supply Status (PSS) Products – Cumulative to November 2021

| Generic Name                           | Presentation   | Brand Name                               | Expiry Date* |
|--|--|--|--------------|
| Abacavir sulphate                      | Tab 300 mg   | Ziagen                                   | 2022         |
| Abacavir sulphate with lamivudine      | Tab 600 mg with lamivudine 300 mg  | Kivexa                                   | 2022         |
| Aciclovir                              | Eye oint 3%, 4.5 g OP<br>Tab dispersible 200 mg, 400 mg & 800 mg   | ViruPOS<br>Lovir                         | 2024<br>2022 |
| Acitretin                              | Cap 10 mg & 25 mg  | Novatrelin                               | 2023         |
| Alendronate sodium                     | Tab 70 mg  | Fosamax                                  | 2022         |
| Alendronate sodium with colecalciferol | Tab 70 mg with colecalciferol 5,600  | Fosamax Plus                             | 2022         |
| Allopurinol                            | Tab 100 mg & 300 mg  | DP-Allopurinol                           | 2023         |
| Ambrisentan                            | Tab 5 mg & 10 mg   | Ambrisentan Mylan                        | 2023         |
| Amiodarone hydrochloride               | inj 50 mg per ml, 3 ml ampoule<br>Tab 100 mg & 200 mg  | Max Health<br>Aratac                     | 2022         |
| Amisulpride                            | Tab 100 mg, 200 mg & 400 mg  | Sulprix                                  | 2022         |
| Amitriptyline                          | Tab 10 mg, 25 mg & 50 mg   | Arrow-Amitriptyline                      | 2023         |
| Amlodipine                             | Tab 2.5 mg, 5 mg & 10 mg   | Vasorex                                  | 2023         |
| Amorolfine                             | Nail soln 5%, 5 ml OP  | MycONail                                 | 2023         |
| Amoxicillin                            | Grans for oral liq 125 mg per 5 ml<br>Grans for oral liq 250 mg per 5 ml<br>Cap 250 mg & 500 mg                | Alphamox 125<br>Alphamox 250<br>Alphamox | 2023<br>2022 |
| Amoxicillin with clavulanic acid       | Tab 500 mg with clavulanic acid 125 mg   | Curam Duo 500/125                        | 2023         |
| Anastrozole                            | Tab 1 mg   | Anatrole                                 | 2023         |
| Apomorphine hydrochloride              | Inj 10 mg per ml, 5 ml ampoule<br>Inj 10 mg per ml, 2 ml ampoule   | Movapo                                   | 2023         |
| Ascorbic acid                          | Tab 100 mg   | Cvite                                    | 2022         |
| Asprin                                 | Tab 100 mg<br>Tab dispersible 300 mg   | Ethics Aspirin EC<br>Ethics Aspirin      | 2022         |
| Atazanavir sulphate                    | Cap 150 mg & 200 mg  | Teva                                     | 2022         |
| Atomoxetine                            | Cap 10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg & 100 mg  | Generic Partners                         | 2022         |
| Atropine sulphate                      | Eye drops 1%, 15 ml OP   | Atropt                                   | 2023         |
| Azathioprine                           | Tab 25 mg & 50 mg  | Azamun                                   | 2022         |
| Bacillus calmette-guerin vaccine       | Inj Mycobacterium bovis BCG (Bacillus Calmette-Guerin), Danish strain 1331, live attenuated, vial with diluent | BCG Vaccine                              | 2024         |
| Bendroflumethiazide [Bendrofluazide]   | Tab 2.5 mg & 5 mg  | Arrow-Bendrofluazide                     | 2023         |

\*Expiry date of the SSS/PSS period is 30 June of the year indicated unless otherwise stated. Please note that SSS/PSS may have been awarded for a wider scope than just those presentation(s) listed in the above table.

## Sole Subsidised Supply (SSS) or Principal Supply Status (PSS) Products – Cumulative to November 2021

| Generic Name                              | Presentation  | Brand Name   | Expiry Date* |
|---|---|--|--------------|
| Benzatropine mesylate                     | Inj 1 mg per ml, 2 ml   | Phebra   | 2023         |
| Benzylpenicillin sodium<br>[Penicillin G] | Inj 600 mg (1 million units) vial   | Sandoz   | 2023         |
| Bethahistine dihydrochloride              | Tab 16 mg   | Vergo 16   | 2023         |
| Betamethasone dipropionate                | Crn & oint 0.05%, 50 g OP   | Diprosone  | 2023         |
| Bicalutamide                              | Tab 50 mg   | Binarex  | 2023         |
| Bisoprolol fumarate                       | Tab 2.5 mg, 5 mg & 10 mg  | Bisoprolol Mylan                                   | 2023         |
| Blood glucose diagnostic test meter       | Meter with 50 lancets, a lancing device and 10 diagnostic test strips, 1 OP | CareSens N<br>CareSens N POP<br>CareSens N Premier | 2022         |
| Blood glucose diagnostic test strip       | Test strips, 50 test OP   | CareSens N<br>CareSens PRO                         | 2022         |
| Blood ketone diagnostic test strip        | Test strips, 10 strip OP  | KetoSens   | 2022         |
| Brinzolamide                              | Eye drops 1%, 5 ml OP   | Azopt  | 2024         |
| Budesonide                                | Metered aqueous nasal spray, 50 mcg & 100 mcg per dose, 200 dose OP         | SteroClear   | 2023         |
| Buprenorphine with naloxone               | Tab sublingual 2 mg with naloxone 0.5 mg & 8 mg with naloxone 2 mg          | Buprenorphine<br>Naloxone BNM                      | 2022         |
| Bupropion hydrochloride                   | Tab modified-release 150 mg   | Zyban  | 2023         |
| Caffeine citrate                          | Oral liq 20 mg per ml (10 mg base per ml), 25 ml OP                         | Biomed   | 2022         |
| Calcitriol                                | Cap 0.25 mcg & 0.5 mcg  | Calcitriol-AFT                                     | 2022         |
| Calcium carbonate                         | Tab 1.25 g (500 mg elemental)   | Calci-Tab 500                                      | 2023         |
| Calcium folinate                          | Inj 10 mg per ml, 5 ml vial   | Calcium Folate<br>Sandoz                           | 2022         |
| Capecitabine                              | Tab 150 mg & 500 mg   | Capercit   | 2022         |
| Capsaicin                                 | Crn 0.025%, 45 g OP<br>Crn 0.075%, 45 g OP                                  | Zostrix<br>Zostrix HP                              | 2023         |
| Cefaclor monohydrate                      | Cap 250 mg<br>Grans for oral liq 125 mg per 5 ml                            | Ranbaxy-Cefaclor                                   | 2022         |
| Cefalexin                                 | Cap 250 mg  | Cefalexin ABM                                      | 2022         |
| Cefazolin                                 | Inj 500 mg & 1 g vial   | AFT  | 2023         |
| Ceftriaxone                               | Inj 500 mg & 1 g vial   | Ceftriaxone-AFT                                    | 2022         |
| Cefuroxime axetil                         | Tab 250 mg  | Zinnat   | 2022         |
| Cetirizine hydrochloride                  | Tab 10 mg   | Zista  | 2022         |
| Cetomacrogol with glycerol                | Crn 90% with glycerol 10%, 500 ml OP & 1,000 ml OP                          | Boucher  | 2022         |

\*Expiry date of the SSS/PSS period is 30 June of the year indicated unless otherwise stated. Please note that SSS/PSS may have been awarded for a wider scope than just those presentation(s) listed in the above table.



## Sole Subsidised Supply (SSS) or Principal Supply Status (PSS) Products – Cumulative to November 2021

| Generic Name                               | Presentation  | Brand Name   | Expiry Date*        |
|--|---|--|---------------------|
| Chloramphenicol                            | Eye oint 1%, 5 g OP<br>Eye drops 0.5%, 10 ml OP   | Devatis<br>Chlorofast  | 2022                |
| Chlorpromazine hydrochloride               | Tab 10 mg, 25 mg & 100 mg<br>Inj 25 mg per ml, 2 ml   | Largactil  | 2022                |
| Chlortalidone [chlorthalidone]             | Tab 25 mg   | Hygroton   | 2022                |
| Cilazapril                                 | Tab 0.5 mg, 2.5 mg & 5 mg   | Zapril   | 2022                |
| <b>Ciprofloxacin</b>                       | <b>Eye drops 0.3%, 5 ml OP</b><br>Tab 250 mg, 500 mg & 750 mg   | <b>Ciprofloxacin Teva</b><br>Cipiflox  | <b>2024</b><br>2023 |
| Clindamycin                                | Cap hydrochloride 150 mg<br>Inj phosphate 150 mg per ml, 4 ml ampoule   | Dalacin C  | 2022                |
| Clobetasol propionate                      | Crn 0.05%, 30 g OP<br>Oint 0.05%, 30 g OP<br>Scalp app 0.05%, 30 ml OP  | Dermol   | 2022                |
| Clonidine                                  | Patch 2.5 mg, 100 mcg per day<br>Patch 5 mg, 200 mcg per day<br>Patch 7.5 mg, 300 mcg per day   | Mylan  | 2023                |
| Clopidogrel                                | Tab 75 mg   | Clopidogrel<br>Multichem   | 2022                |
| Clotrimazole                               | Vaginal crm 1% with applicators,<br>35 g OP<br>Vaginal crm 2% with applicators,<br>20 g OP  | Clomazol   | 2022                |
| Coal tar                                   | Soln BP   | Midwest  | 2022                |
| Codeine phosphate                          | Tab 15 mg, 30 mg & 60 mg  | PSM  | 2023                |
| Colecalciferol                             | Cap 1.25 mg (50,000 iu)   | Vit.D3   | 2023                |
| Compound electrolytes                      | Powder for oral soln  | Electral   | 2022                |
| Compound hydroxybenzoate                   | Soln  | Midwest  | 2022                |
| Condoms                                    | 60 mm<br>49 mm<br>53 mm, 0.05 mm thickness<br>53 mm<br>53 mm, strawberry, red<br>53 mm, chocolate, brown<br>56 mm<br>56 mm, 0.08 mm thickness<br>56 mm, 0.08 mm thickness, red<br>56 mm, 0.05 mm thickness<br>56 mm, chocolate<br>56 mm, strawberry | Shield XL<br>Gold Knight<br>Moments<br><br><br><br><br><br><br><br><br><br>Gold Knight | 30/09/2022          |
| Cyclizine lactate                          | Inj 50 mg per ml, 1 ml  | Hameln   | 2022                |
| Cyproterone acetate with ethinyloestradiol | Tab 2 mg with ethinyloestradiol 35 mcg and 7 inert tabs   | Ginet  | 2023                |
| Darunavir                                  | Tab 400 mg & 600 mg   | Darunavir Mylan  | 2023                |

\*Expiry date of the SSS/PSS period is 30 June of the year indicated unless otherwise stated. Please note that SSS/PSS may have been awarded for a wider scope than just those presentation(s) listed in the above table.

## Sole Subsidised Supply (SSS) or Principal Supply Status (PSS) Products – Cumulative to November 2021

| Generic Name   | Presentation  | Brand Name                                       | Expiry Date* |
|--|---|--|--------------|
| Desmopressin acetate   | Nasal spray 10 mcg per dos, 6 ml OP   | Desmopressin-PH&T                                | 2023         |
| Dexamethasone phosphate  | Inj 4 mg per ml, 1 ml & 2 ml ampoule  | Dexamethasone Phosphate Panpharma                | 2022         |
| Diazepam   | Tab 2 mg & 5 mg   | Arrow-Diazepam                                   | 2023         |
| <b>Diclofenac</b>  | <b>Eye drops 0.1%; 5 ml OP</b>  | <b>Voltaren Ophtha</b>                           | <b>2024</b>  |
| Digoxin  | Tab 62.5 mcg<br>Tab 240 mcg   | Lanoxin PG<br>Lanoxin                            | 2022         |
| Dihydrocodeine tartrate  | Tab long-acting 60 mg   | DHC Continus                                     | 2022         |
| Dimethicone  | Crn 5% pump bottle, 500 ml OP<br>Lotn 4%, 200 ml OP   | healthE Dimethicone 5%<br>healthE Dimethicone 4% | 2022         |
| Diphtheria, tetanus and pertussis vaccine  | Inj 2 IU diphtheria toxoid with 20 IU tetanus toxoid, 8 mcg pertussis toxoid, 8 mcg pertussis filamentous haemagglutinin and 2.5 mcg pertactin in 0.5 ml syringe  | Boostrix   | 2024         |
| Diphtheria, tetanus, pertussis and polio vaccine   | Inj 30 IU diphtheria toxoid with 40 IU tetanus toxoid, 25 mcg pertussis toxoid, 25 mcg pertussis filamentous haemagglutinin, 8 mcg pertactin and 80 D-antigen units poliomyelitis virus in 0.5ml syringe                | Infanrix IPV                                     | 2024         |
| Diphtheria, tetanus, pertussis, polio, hepatitis B and haemophilus influenzae type B vaccine | Inj 30 IU diphtheria toxoid with 40 IU tetanus toxoid, 25 mcg pertussis toxoid, 25 mcg pertussis filamentous haemagglutinin, 8 mcg pertactin, 80 D-AgU polio virus, 10 mcg hepatitis B surface antigen in 0.5ml syringe | Infanrix-hexa                                    | 2024         |
| Dipyridamole   | Tab long-acting 150 mg  | Pytazen SR                                       | 2022         |
| <b>Disulfiram</b>  | <b>Tab 200 mg</b>   | <b>Antabuse</b>                                  | <b>2024</b>  |
| Docusate sodium  | Tab 50 mg & 120 mg  | Coloxyl  | 2023         |
| Donepezil hydrochloride  | Tab 5 mg & 10 mg  | Donepezil-Rex                                    | 2023         |
| Dual blood glucose and blood ketone diagnostic test meter                                    | Meter with 50 lancets, a lancing device and 10 blood glucose diagnostic test strips, 1 OP   | CareSens Dual                                    | 2022         |
| Efavirenz with emtricitabine and tenofovir disoproxil  | Tab 600 mg with emtricitabine 200 mg and tenofovir disoproxil 245 mg (300 mg as a maleate)  | Mylan  | 2022         |
| Emtricitabine  | Cap 200 mg  | Emtriva  | 2022         |
| Emtricitabine with tenofovir disoproxil  | Tab 200 mg with tenofovir disoproxil 245 mg (300.6 mg as a succinate)   | Teva   | 2022         |

\*Expiry date of the SSS/PSS period is 30 June of the year indicated unless otherwise stated. Please note that SSS/PSS may have been awarded for a wider scope than just those presentation(s) listed in the above table.

## Sole Subsidised Supply (SSS) or Principal Supply Status (PSS) Products – Cumulative to November 2021

| Generic Name                        | Presentation  | Brand Name   | Expiry Date* |
|-------------------------------------|---|--|--------------|
| Emulsifying ointment                | Oint BP   | Emulsifying Ointment ADE                             | 2023         |
| Enalapril maleate                   | Tab 5 mg, 10 mg & 20 mg   | Acetec   | 2022         |
| Epoetin alfa                        | Inj 1,000 iu in 0.5 ml, syringe<br>Inj 2,000 iu in 1 ml, syringe<br>Inj 3,000 iu in 0.3 ml, syringe<br>Inj 4,000 iu in 0.4 ml, syringe<br>Inj 5,000 iu in 0.5 ml, syringe<br>Inj 6,000 iu in 0.6 ml, syringe<br>Inj 8,000 iu in 0.8 ml, syringe<br>Inj 10,000 iu in 1 ml, syringe<br>Inj 40,000 iu in 1 ml, syringe | Binocrit   | 2022         |
| Erythromycin (as lactobionate)      | Inj 1 g vial  | Erythrocin IV  | 2022         |
| Escitalopram                        | Tab 10 mg & 20 mg   | Escitalopram (Ethics)                                | 2024         |
| Etanercept                          | Inj 25 mg<br>Inj 50 mg autoinjector<br>Inj 50 mg prefilled syringe  | Enbrel   | 2024         |
| Ethinylestradiol and norethisterone | Tab 35 mcg with norethisterone 1 mg and 7 inert tab   | Brevinor 1/28  | 2022         |
| Etoposide                           | Cap 50 mg & 100 mg  | Vepesid  | 2022         |
| Ezetimibe                           | Tab 10 mg   | Ezetimibe Sandoz                                     | 2023         |
| Ferrous sulfate                     | Oral liq 30 mg (6 mg elemental) per ml  | Ferodan  | 2022         |
| Finasteride                         | Tab 5 mg  | Ricit  | 2023         |
| Flecainide acetate                  | Tab 50 mg<br>Cap long-acting 100 mg & 200 mg  | Flecainide BNM<br>Flecainide Controlled Release Teva | 2022         |
| Flucloxacillin                      | Inj 1 g vial  | Flucil   | 2023         |
| Fluconazole                         | Cap 50 mg, 150 mg & 200 mg  | Mylan  | 2023         |
| Fluticasone                         | Aerosol inhaler 50 mcg, 125 mcg & 250mcg per dose, 120 dose OP  | Flixotide  | 2023         |
| Fluticasone with salmeterol         | Aerosol inhaler 50 mcg with salmeterol 25 mcg & 125 mcg with salmeterol 25 mcg, 120 dose OP   | Seretide   | 2023         |
| Furosemide [frusemide]              | Inj 10 mg per ml, 25 ml ampoule<br>Oral liq 10 mg per ml, 30 ml OP<br>Inj 10 mg per ml, 2 ml ampoule  | Lasix<br>Frusemide-Baxter                            | 2022         |
| Gliclazide                          | Tab 80 mg   | Glizide  | 2023         |
| Glucagon hydrochloride              | Inj 1 mg syringe kit  | Glucagen Hypokit                                     | 2023         |
| Glucose [Dextrose]                  | Inj 50%, 10 ml ampoule<br>Inj 50%, 90 ml bottle   | Biomed   | 2023         |

\*Expiry date of the SSS/PSS period is 30 June of the year indicated unless otherwise stated. Please note that SSS/PSS may have been awarded for a wider scope than just those presentation(s) listed in the above table.

## Sole Subsidised Supply (SSS) or Principal Supply Status (PSS) Products – Cumulative to November 2021

| Generic Name  | Presentation   | Brand Name   | Expiry Date*        |
|---|--|--|---------------------|
| Glycerin with sodium saccharin  | Suspension   | Ora-Sweet SF   | 2022                |
| Glycerin with sucrose   | Suspension   | Ora-Sweet  | 2022                |
| Glycerol  | Liquid   | healthE Glycerol BP  | 2023                |
| Glyceryl trinitrate   | Oint 0.2%, 30 g OP   | Rectogesic   | 2024                |
| Goserelin   | Implant 3.6 mg & 10.8 mg, syringe  | Teva   | 2023                |
| Haloperidol   | Inj 5 mg per ml, 1 ml ampoule<br>Oral liq 2 mg per ml<br>Tab 500 mcg, 1.5 mg & 5 mg                            | Serenace   | 2022                |
| Hepatitis A vaccine   | Inj 1440 ELISA units in 1 ml syringe<br>Inj 720 ELISA units in 0.5 ml syringe                                  | Havrix<br>Havrix Junior  | 2024                |
| Hepatitis B recombinant vaccine   | Inj 20 mcg per 1 ml prefilled syringe  | Engerix-B  | 2024                |
| Human papillomavirus (6, 11, 16, 18, 31, 33, 45, 52 and 58) vaccine [HPV] | Inj 270 mg in 0.5 ml syringe   | Gardasil 9   | 2024                |
| <b>Hydrocortisone</b>   | <b>Inj 100 mg vial</b><br>Crm 1%, 500 g<br>Crm 1%, 100 g OP  | <b>Solu-Cortef</b><br>Hydrocortisone (PSM)                         | <b>2024</b><br>2022 |
| Hydrocortisone and paraffin liquid and lanolin                            | Lotn 1% with paraffin liquid 15.9% and lanolin 0.6%  | DP Lotn HC   | 2023                |
| Hydroxyurea [hydroxycarbamide]  | Cap 500 mg   | Devatis  | 2023                |
| Hyoscine butylbromide   | Tab 10 mg<br>Inj 20 mg, 1 ml   | Buscopan   | 2023                |
| Ibuprofen   | Tab 200 mg   | Relieve  | 2024                |
| Iloprost  | Nebuliser soln 10 mcg per ml, 2 ml   | Ventavis   | 2022                |
| Imatinib mesylate   | Cap 100 mg & 400 mg  | Imatinib-Rex   | 2023                |
| Indapamide  | Tab 2.5 mg   | Dapa-Tabs  | 2023                |
| Intra-uterine device  | IUD 29.1 mm length x 23.2 mm width<br>IUD 33.6 mm length x 29.9 mm width<br>IUD 35.5 mm length x 19.6 mm width | Choice TT380 Short<br><br>Choice TT380 Standard<br>Choice Load 375 | 2022                |
| Ipratropium bromide   | Aqueous nasal spray, 0.03%, 15 ml OP<br><br>Nebuliser soln, 250 mcg per ml, 2 ml ampoule                       | Univent  | 2023<br><br>2022    |
| Isosorbide mononitrate  | Tab 20 mg<br>Tab long-acting 40 mg<br>Tab long-acting 60 mg  | ISMO 20<br>ISMO 40 Retard<br>Duride                                | 2023                |
| Ispaghula (psyllium) husk   | Powder for oral soln, 500 g OP   | Konsyl-D   | 2023                |
| Itraconazole  | Cap 100 mg   | Itrazole   | 2022                |

\*Expiry date of the SSS/PSS period is 30 June of the year indicated unless otherwise stated. Please note that SSS/PSS may have been awarded for a wider scope than just those presentation(s) listed in the above table.

## Sole Subsidised Supply (SSS) or Principal Supply Status (PSS) Products – Cumulative to November 2021

| Generic Name   | Presentation   | Brand Name   | Expiry Date*               |
|--|--|--|----------------------------|
| Ketoconazole   | Shampoo 2%, 100 ml OP  | Sebizole   | 2023                       |
| Labetalol  | Tab 100 mg & 200 mg  | Trandate   | 2024                       |
| Lactulose  | Oral liq 10 g per 15 ml  | Laevolac   | 2022                       |
| Lamivudine   | Tab 100 mg<br>Tab 150 mg   | Zetlam<br>Lamivudine<br>Alphapharm                       | 2023                       |
| Lamotrigine  | Tab dispersible 25 mg, 50 mg &<br>100 mg   | Logem  | 2022                       |
| Latanoprost with timolol   | Eye drops 0.005% with timolol 0.5%,<br>2.5 ml OP   | Arrow - Lattim   | 2023                       |
| Leflunomide  | Tab 10 mg & 20 mg  | Arava  | 2023                       |
| Levetiracetam  | Tab 250 mg, 500 mg, 750 mg and<br>1,000 mg   | Everet   | 2022                       |
| Levodopa with carbidopa  | Tab long-acting 200 mg with<br>carbidopa 50 mg<br>Tab 100 mg with carbidopa 25 mg &<br>250 mg with carbidopa 25 mg               | Sinemet CR<br>Sinemet                                    | 2023                       |
| Levomepromazine<br>hydrochloride   | Inj 25 mg per ml, 1 ml ampoule   | Nozinan  | 2022                       |
| Levomepromazine maleate  | Tab 25 mg & 100 mg   | Nozinan  | 2022                       |
| Levonorgestrel   | Subdermal implant (2 x 75 mg rods)<br>Tab 30 mcg<br>Intra-uterine device system 52 mg<br>Intra-uterine device system 13.5 mg     | Jadelle<br>Microlut<br>Mirena<br>Jaydess                 | 2023<br>2022<br>31/10/2022 |
| Lidocaine [Lignocaine]   | Gel 2%, 11 ml urethral syringe   | Instillagel Lido   | 2022                       |
| Lidocaine [lignocaine]<br>hydrochloride  | Inj 2%, 5 ml ampoule<br>Inj 1%, 20 ml vial<br>Inj 2%, 20 ml vial   | Lidocaine-Baxter<br>Lidocaine-Claris<br>Lidocaine-Baxter | 2022                       |
| Lithium carbonate  | Tab long-acting 400 mg   | Priadel  | 2024                       |
| Loperamide hydrochloride   | Cap 2 mg   | Diamide Relief   | 2022                       |
| Loratadine   | Oral liq 1 mg per ml<br>Tab 10 mg  | Haylor syrup<br>Lorafix                                  | 2022                       |
| Losartan potassium   | Tab 12.5 mg, 25 mg, 50 mg<br>& 100 mg  | Losartan Actavis   | 2023                       |
| Macrogol 3350 with<br>potassium chloride,<br>sodium bicarbonate and<br>sodium chloride | Powder for oral soln 13.125 g with<br>potassium chloride 46.6 mg,<br>sodium bicarbonate 178.5 mg and<br>sodium chloride 350.7 mg | Molaxole   | 2023                       |
| Magnesium sulphate   | Inj 2 mmol per ml, 5 ml ampoule  | Martindale   | 2023                       |

\*Expiry date of the SSS/PSS period is 30 June of the year indicated unless otherwise stated. Please note that SSS/PSS may have been awarded for a wider scope than just those presentation(s) listed in the above table.

## Sole Subsidised Supply (SSS) or Principal Supply Status (PSS) Products – Cumulative to November 2021

| Generic Name   | Presentation  | Brand Name                             | Expiry Date* |
|--|---|--|--------------|
| Measles, mumps and rubella vaccine                         | Inj, measles virus 1,000 CCID50, mumps virus 5,012 CCID50, Rubella virus 1,000 CCID50; prefilled syringe/ampoule of diluent 0.5 ml        | Priorix                                | 2024         |
| Mebeverine hydrochloride                                   | Tab 135 mg  | Colofac                                | 2023         |
| Medroxyprogesterone acetate                                | Inj 150 mg per ml, 1 ml syringe   | Depo-Provera                           | 2022         |
| Meningococcal (groups A, C, Y and W-135) conjugate vaccine | Inj 4 mcg of each meningococcal polysaccharide conjugated to a total of approximately 48 mcg of diphtheria toxoid carrier per 0.5 ml vial | Menactra                               | 2024         |
| Mercaptopurine   | Tab 50 mg   | Puri-nethol                            | 2022         |
| Mesalazine   | Tab long-acting 500 mg  | Pentasa                                | 2023         |
| Mesna  | Tab 400 mg & 600 mg   | Uromitexan                             | 2022         |
| Methadone hydrochloride                                    | Tab 5 mg  | Methatabs                              | 2022         |
| Methotrexate   | Inj 100 mg per ml, 50 ml vial   | Methotrexate Ebewe                     | 2023         |
| Methylcellulose  | Powder<br>Suspension  | Midwest<br>Ora Plus                    | 2022         |
| Methylcellulose with glycerin and sodium saccharin         | Suspension  | Ora Blend SF                           | 2022         |
| Methylcellulose with glycerin and sucrose                  | Suspension  | Ora Blend                              | 2022         |
| Methyl hydroxybenzoate                                     | Powder  | Midwest                                | 2022         |
| Methylprednisolone aceponate                               | Crn & oint 0.1%, 15 g OP  | Advantan                               | 2023         |
| Metoclopramide hydrochloride                               | Tab 10 mg<br>Inj 5 mg per ml, 2 ml ampoule  | Metoclopramide<br>Actavis 10<br>Pfizer | 2023<br>2022 |
| Metoprolol tartrate  | Inj 1 mg per ml, 5 ml vial  | Metoprolol IV Mylan                    | 01/02/2022   |
| Metronidazole  | Tab 200 mg & 400 mg   | Metrogyl                               | 2023         |
| Metyrapone   | Cap 250 mg  | Metopirone                             | 2023         |
| Miconazole nitrate   | Crn 2%, 15 g OP<br>Vaginal crn 2% with applicator, 40 g OP  | Multichem<br>Micreme                   | 2023         |
| Montelukast  | Tab 4 mg, 5 mg & 10 mg  | Montelukast Mylan                      | 2022         |
| Morphine sulphate  | Tab immediate-release 10 mg & 20 mg<br>Cap long-acting 10 mg, 30 mg, 60 mg & 100 mg   | Sevredol<br>m-Eslon                    | 2023<br>2022 |
| Moxifloxacin   | Tab 400 mg  | Avelox                                 | 2023         |

\*Expiry date of the SSS/PSS period is 30 June of the year indicated unless otherwise stated. Please note that SSS/PSS may have been awarded for a wider scope than just those presentation(s) listed in the above table.

## Sole Subsidised Supply (SSS) or Principal Supply Status (PSS) Products – Cumulative to November 2021

| Generic Name   | Presentation   | Brand Name                  | Expiry Date* |
|--|--|-----------------------------|--------------|
| Multivitamins  | Tab (BPC cap strength)   | Mvite                       | 2022         |
| Naltrexone hydrochloride                                 | Tab 50 mg  | Naltraccord                 | 2023         |
| Nicorandil   | Tab 10 mg & 20 mg  | Ikorel                      | 2022         |
| Nitrofurantoin   | Cap modified-release 100 mg  | Macrobid                    | 2023         |
| Nortriptyline hydrochloride                              | Tab 10 mg & 25 mg  | Norpress                    | 2022         |
| Nystatin   | Oral liq 100,000 u per ml, 24 ml OP<br>Vaginal crm 100,000 u per 5 g with applicator(s), 75 g OP | Nilstat                     | 2023         |
| Oestriol   | Crm 1 mg per g with applicator,<br>15 g OP   | Ovestin                     | 2023         |
|  | Pessaries 500 mcg<br>Tab 2 mg  | Ovestin                     |              |
| Olanzapine   | Orodispersible tab 5 mg & 10 mg  | Zypine ODT                  | 2023         |
|  | Tab 2.5 mg, 5 mg and 10 mg   | Zypine                      |              |
| Olopatadine  | Eye drops 0.1%, 5 ml OP  | Olopatadine Teva            | 2022         |
| Omeprazole   | Cap 10 mg  | Omeprazole actavis<br>10    | 2023         |
|  | Cap 20 mg  | Omeprazole actavis<br>20    |              |
|  | Cap 40 mg  | Omeprazole actavis<br>40    |              |
|  | Inj 40 mg ampoule with diluent   | Dr Reddy's<br>Omeprazole    | 2022         |
| Ondansetron  | Tab disp 4 mg & 8 mg   | Ondansetron ODT-<br>DRLA    | 2023         |
|  | Tab 4 mg & 8 mg  | Onrex                       | 2022         |
| Oxycodone hydrochloride                                  | Oral liq 5 mg per 5 ml   | OxyNorm                     | 2024         |
| Pantoprazole   | Tab EC 20 mg & 40 mg   | Panzop Relief               | 2022         |
| Paracetamol  | Oral liq 120 mg per 5 ml   | Paracare                    | 2023         |
|  | Oral liq 250 mg per 5 ml   | Paracare Double<br>Strength |              |
| Paraffin   | White soft, 500 g & 2,500 g  | healthE                     | 2022         |
| Paroxetine   | Tab 20 mg  | Loxamine                    | 2022         |
| Perhexiline maleate                                      | Tab 100 mg   | Pexsig                      | 2022         |
| Permethrin   | Crm 5%, 30 g OP  | Lyderm<br>A-Scabies         | 2023         |
|  | Lotn 5%, 30 ml OP  |                             |              |
| Phenoxyethylpenicillin<br>(penicillin V)                 | Grans for oral liq 125 mg per 5 ml   | AFT                         | 2022         |
|  | Grans for oral liq 250 mg per 5 ml   |                             |              |
| Pimecrolimus   | Crm 1%, 15 g OP  | Elidel                      | 2023         |
| Pine tar with trolamine<br>laurilsulfate and fluorescein | Soln 2.3% with trolamine laurilsulfate<br>and fluorescein sodium                                 | Pinetarsol                  | 2023         |

\*Expiry date of the SSS/PSS period is 30 June of the year indicated unless otherwise stated. Please note that SSS/PSS may have been awarded for a wider scope than just those presentation(s) listed in the above table.

## Sole Subsidised Supply (SSS) or Principal Supply Status (PSS) Products – Cumulative to November 2021

| Generic Name                                | Presentation   | Brand Name                     | Expiry Date* |
|---|--|--------------------------------|--------------|
| Pneumococcal (PCV10) conjugate vaccine      | Inj 1 mcg of pneumococcal polysaccharide serotypes 1, 5, 6B, 7F, 9V, 14 and 23F; 3 mcg of pneumococcal polysaccharide serotypes 4, 18C and 19F in 0.5 ml prefilled syringe | Synflorix                      | 2024         |
| Pneumococcal (PPV23) polysaccharide vaccine | Inj 575 mcg in 0.5 ml prefilled syringe (25 mcg of each 23 pneumococcal serotype)  | Pneumovax 23                   | 2024         |
| Poliomyelitis vaccine                       | Inj 80D antigen units in 0.5 ml syringe  | IPOL                           | 2024         |
| Poloxamer                                   | Oral drops 10%, 30 ml OP   | Coloxyl                        | 2023         |
| Potassium iodate                            | Tab 253 mcg (150 mcg elemental iodine)   | NeuroTabs                      | 2023         |
| Povidone iodine                             | Oint 10%, 65 g OP  | Betadine                       | 2023         |
| Pramipexole hydrochloride                   | Tab 0.25 mg & 1 mg   | Ramipex                        | 2022         |
| Pravastatin                                 | Tab 20 mg & 40 mg  | Pravastatin Mylan              | 2023         |
| Prochlorperazine                            | Tab 5 mg   | Nausafix                       | 2023         |
| Pyridostigmine bromide                      | Tab 60 mg  | Mestinon                       | 2022         |
| Pyridoxine hydrochloride                    | Tab 25 mg  | Vitamin B6 25                  | 2023         |
| Quetiapine                                  | Tab 25 mg, 100 mg, 200 mg & 300 mg   | Quetapel                       | 2023         |
| Rifampicin                                  | Cap 150 mg & 300 mg<br>Oral liq 100 mg per 5 ml  | Rifadin                        | 2023         |
| Rifaximin                                   | Tab 550 mg   | Xifaxan                        | 2023         |
| Risedronate sodium                          | Tab 35 mg  | Risedronate Sandoz             | 2022         |
| Risperidone                                 | Tab 0.5 mg, 1 mg, 2 mg, 3 mg & 4 mg<br>Oral liq 1 mg per ml  | Risperidone (Teva)<br>Risperon | 2023         |
| Ritonavir                                   | Tab 100 mg   | Norvir                         | 2022         |
| Rituximab                                   | Inj 100 mg per 10 ml vial & 500 mg per 50 ml vial  | Riximyo                        | 30/09/2023   |
| Rizatriptan                                 | Tab orodispersible 10 mg   | Rizamelt                       | 2023         |
| Ropinirole hydrochloride                    | Tab 0.25 mg, 1 mg, 2 mg & 5 mg   | Ropin                          | 2022         |
| Rotavirus oral vaccine                      | Oral susp live attenuated human rotavirus 1,000,000 CCID50 per dose, prefilled oral applicator   | Rotarix                        | 2024         |
| Roxithromycin                               | Tab 150 mg & 300 mg  | Arrow-Roxithromycin            | 2022         |
| Sertraline                                  | Tab 50 mg & 100 mg   | Setrona                        | 2022         |
| Simvastatin                                 | Tab 10 mg, 20 mg, 40 mg & 80 mg  | Simvastatin Mylan              | 2023         |
| Sodium bicarbonate                          | Powder BP  | Midwest                        | 2022         |

\*Expiry date of the SSS/PSS period is 30 June of the year indicated unless otherwise stated. Please note that SSS/PSS may have been awarded for a wider scope than just those presentation(s) listed in the above table.



## Sole Subsidised Supply (SSS) or Principal Supply Status (PSS) Products – Cumulative to November 2021

| Generic Name                                    | Presentation   | Brand Name   | Expiry Date* |
|---|--|--|--------------|
| Sodium chloride                                 | Inj 0.9%, 5 ml ampoule, 10 ml ampoule & 20 ml ampoule<br>Nebuliser soln, 7%, 90 ml OP                                | Fresenius Kabi<br>Biomed   | 2022         |
| Sodium citrate with sodium lauryl sulphoacetate | Enema 90 mg with sodium lauryl sulphoacetate 9 mg per ml, 5 ml   | Micolette  | 2022         |
| Sodium citro-tartrate                           | Grans eff 4 g sachets  | Ural   | 2023         |
| Sodium cromoglicate                             | Eye drops 2%, 5 ml OP  | Rexacrom   | 2022         |
| Sotalol   | Tab 80 mg & 160 mg   | Mylan  | 2022         |
| Spironolactone                                  | Oral liq 5 mg per ml, 25 ml OP   | Biomed   | 2022         |
| Sulfasalazine                                   | Tab EC 500 mg  | Salazopyrin EN   | 2022         |
| Sumatriptan                                     | Inj 12 mg per ml, 0.5 ml prefilled pen, 2 OP   | Imigran  | 2022         |
| Sunscreen, proprietary                          | Lotn, 200 g OP   | Marine Blue Lotion<br>SPF 50+                                      | 2022         |
| Syrup (pharmaceutical grade)                    | Liq  | Midwest  | 2022         |
| Taliglucerase alfa                              | Inj 200 unit vial  | Elelyso  | 2023         |
| Tamoxifen citrate                               | Tab 10 mg & 20 mg  | Tamoxifen Sandoz   | 2023         |
| Tamsulosin hydrochloride                        | Cap 400 mcg  | Tamsulosin-Rex   | 2022         |
| Temazepam                                       | Tab 10 mg  | Normison   | 2023         |
| Temozolomide                                    | Cap 5 mg, 20 mg, 100 mg, 140 mg & 250 mg   | Temaccord  | 2022         |
| Tenoxicam                                       | Tab 20 mg  | Tilocotil  | 2022         |
| Terbinafine                                     | Tab 250 mg   | Deolate  | 2023         |
| Teriflunomide                                   | Tab 14 mg  | Aubagio  | 2023         |
| Tetrabenazine                                   | Tab 25 mg  | Motetis  | 2022         |
| Theophylline                                    | Tab long-acting 250 mg<br>Oral liq 80 mg per 15 ml   | Nuelin-SR<br>Nuelin  | 2022         |
| Timolol   | Eye drops 0.25% & 0.5%, 5 ml OP  | Arrow-Timolol  | 2023         |
| Tobramycin                                      | Solution for inhalation 60 mg per ml, 5 ml   | Tobramycin BNM   | 2023         |
| Tramadol hydrochloride                          | Cap 50 mg<br>Tab sustained-release 100 mg<br>Tab sustained-release 150 mg<br>Tab sustained-release 200 mg            | Arrow-Tramadol<br>Tramal SR 100<br>Tramal SR 150<br>Tramal SR 200  | 2023         |
| Tranexamic acid                                 | Tab 500 mg   | Mercury Pharma   | 2022         |
| Triamcinolone acetonide                         | Inj 10 mg per ml, 1 ml ampoule<br>Inj 40 mg per ml, 1 ml ampoule<br>Paste 0.1%, 5 g OP<br>Crm & oint 0.02%, 100 g OP | Kenacort-A 10<br>Kenacort-A 40<br>Kenalog in Orabase<br>Aristocort | 2023         |

\*Expiry date of the SSS/PSS period is 30 June of the year indicated unless otherwise stated. Please note that SSS/PSS may have been awarded for a wider scope than just those presentation(s) listed in the above table.

## Sole Subsidised Supply (SSS) or Principal Supply Status (PSS) Products – Cumulative to November 2021

| <b>Generic Name</b>                    | <b>Presentation</b>                         | <b>Brand Name</b> | <b>Expiry Date*</b> |
|--|---|-------------------|---------------------|
| Tuberculin PPD [Mantoux] test          | Inj 5 TU per 0.1 ml, 1 ml vial              | Tubersol          | 2024                |
| Ursodeoxycholic acid                   | Cap 250 mg                                  | Ursosan           | 2023                |
| Vancomycin                             | Inj 500 mg vial                             | Mylan             | 2023                |
| Varicella vaccine [Chickenpox vaccine] | Inj 1350 PFU prefilled syringe              | Varivax           | 2024                |
| Zinc sulphate                          | Cap 137.4 mg (50 mg elemental)              | Zincaps           | 2022                |
| Zoledronic acid                        | Inj 0.05 mg per ml, 100 ml, vial, 100 ml OP | Aclasta           | 2022                |

**November changes are in bold type**

---

*\*Expiry date of the SSS/PSS period is 30 June of the year indicated unless otherwise stated. Please note that SSS/PSS may have been awarded for a wider scope than just those presentation(s) listed in the above table.*

Check your Schedule for full details  
Schedule page ref

Subsidy  
(Mnfr's price)  
\$ Per

Brand or  
Generic Mnfr  
✓ fully subsidised

## New Listings

Effective 1 November 2021

|     |  |                       |                   |   |
|-----|--|-----------------------|-------------------|---|
| 34  | PYRIDOXINE HYDROCHLORIDE<br>a) No more than 100 mg per dose<br>b) Only on a prescription<br>Tab 50 mg.....   | 23.45                 | 500               | ✓ Pyridoxine multichem  |
| 39  | FOLIC ACID<br>Tab 0.8 mg.....  | 26.60                 | 1,000             | ✓ Folic Acid multichem  |
| 48  | PRAZOSIN<br>* Tab 1 mg.....<br>* Tab 2 mg.....<br>* Tab 5 mg.....<br>Wastage claimable   | 5.53<br>7.00<br>11.70 | 100<br>100<br>100 | ✓ Apo-Prazosin S29<br>S29<br>✓ Apo-Prazosin S29<br>S29<br>✓ Apo-Prazosin S29<br>S29 |
| 55  | METHYLDOPA<br>* Tab 250 mg.....<br>Note – this listing is for Pharmacode 2603934.  | 15.10                 | 100               | ✓ Methyldopa Mylan  |
| 66  | AQUEOUS CREAM<br>* Crm.....  | 1.73                  | 500 g             | ✓ GEM Aqueous Cream   |
| 72  | KETOCONAZOLE<br>Shampoo 2%.....<br>a) Maximum of 100 ml per prescription<br>b) Only on a prescription<br>Note – this is a listing for Pharmacode 361410. | 3.23                  | 100 ml OP         | ✓ <u>Sebizole</u>   |
| 79  | CINACALCET – Special Authority see SA1618 – Retail pharmacy<br>Tab 30 mg – Wastage claimable .....<br>Tab 60 mg – Wastage claimable .....                | 42.06<br>84.12        | 28<br>28          | ✓ Cinacalcet Devatis<br>✓ Cinacalcet Devatis  |
| 108 | DARUNAVIR – Special Authority see SA1651 – Retail pharmacy<br>Tab 400 mg.....<br>Note – this listing is for Pharmacode 2591286.                          | 132.00                | 60                | ✓ <u>Darunavir Mylan</u>  |
| 120 | ENTACAPONE<br>▲ Tab 200 mg.....  | 18.04                 | 100               | ✓ Comtan  |
| 136 | AMISULPRIDE – Safety medicine; prescriber may determine dispensing frequency<br>Tab 100 mg.....<br>Note – this listing is for Pharmacode 2609401.        | 5.15                  | 30                | ✓ <u>Sulprix</u>  |
| 140 | MELATONIN – Special Authority see SA1666 – Retail pharmacy<br>Tab modified-release 2 mg – No more than 5 tab per day.....                                | 11.50                 | 30                | ✓ Vigisom   |

▲ Three months supply may be dispensed at one time if endorsed  
“certified exemption” by the prescriber or pharmacist

\* Three months or six months, as  
applicable, dispensed all-at-once

Check your Schedule for full details  
Schedule page ref

Subsidy  
(Mnfr's price)  
\$ Per

Brand or  
Generic Mnfr  
✓ fully subsidised

### New Listings – effective 1 November 2021 (continued)

|     |   |       |   |                                 |
|-----|---|-------|---|---------------------------------|
| 156 | BORTEZOMIB – PCT only – Specialist – Special Authority see SA1889<br>Inj 2.5 mg vial..... | 75.00 | 1 | ✓ <b>Bortezomib Juno</b><br>S29 |
|-----|---|-------|---|---------------------------------|

### Effective 4 October 2021

|     |   |        |   |   |
|-----|---|--------|---|---|
| 156 | BORTEZOMIB – PCT only – Specialist – Special Authority see SA1889<br>Inj 3.5 mg vial..... | 105.00 | 1 | ✓ <b>Bortezomib Dr Reddy's</b><br>S29 S29 |
|-----|---|--------|---|---|

## Changes to Restrictions, Chemical Names and Presentations Effective 1 November 2021

|    |   |        |       |   |  |
|----|---|--------|-------|---|--|
| 48 | <b>PRAZOSIN – Subsidy by endorsement (removal of subsidy by endorsement)</b><br>Subsidy by endorsement – Subsidised for patients who were taking prazosin prior to 1 August 2021 and the prescription is endorsed accordingly. Pharmacists may annotate the prescription as endorsed where there exists a record of prior dispensing of prazosin.         |        |       |   |  |
|    | * Tab 1 mg.....   | 5.53   | 100   | ✓ Apo-Prazosin<br>✓ Apo-Prazosin S29<br>S29 |  |
|    | * Tab 2 mg.....   | 7.00   | 100   | ✓ Apo-Prazosin<br>✓ Apo-Prazosin S29<br>S29 |  |
|    | * Tab 5 mg.....   | 11.70  | 100   | ✓ Apo-Prazosin<br>✓ Apo-Prazosin S29<br>S29 |  |
| 82 | <b>TESTOSTERONE UNDECANOATE (addition of subsidy by endorsement)</b><br>Cap 40 mg – <b>Subsidy by endorsement</b> .....21.00  |        | 60    | ✓ Andriol Testocaps                         |  |
|    | <b>Subsidy by endorsement – subsidised for patients who were taking testosterone undecanoate cap 40 mg prior to 1 November 2021 and the prescription is endorsed accordingly. Pharmacists may annotate the prescription as endorsed where there exists a record of prior dispensing of testosterone undecanoate cap 40 mg in the preceding 12 months.</b> |        |       |   |  |
| 83 | <b>OESTRADIOL VALERATE (removal of stat dispensing)</b><br>* Tab 2 mg.....  | 12.36  | 84    | ✓ Progynova                                 |  |
| 92 | <b>CLARITHROMYCIN – Maximum of 500 mg per prescription; can be waived by Special Authority see SA1857 (amended restriction criteria)</b><br>Tab 250 mg – <b>Maximum of 56 tab per prescription; can be waived by Special Authority see SA1857</b> .....   | 3.98   | 14    | ✓ Apo-Clarithromycin<br>✓ Klacid            |  |
|    | Grans for oral liq 250 mg per 5 ml .....  | 8.53   |       | ✓ Klacid                                    |  |
|    | a) <b>Maximum of 500 mg per prescription; can be waived by Special Authority see SA1857</b>   | 192.00 | 50 ml | ✓ Klacid                                    |  |
|    | b) Wastage claimable  |        |       |   |  |

▲ Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber or pharmacist

\* Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details  
Schedule page ref

Subsidy  
(Mnfr's price)  
\$ Per

Brand or  
Generic Mnfr  
✓ fully subsidised

## Changes to Restrictions – effective 1 November 2021 (continued)

|     |   |        |      |            |
|-----|---|--------|------|------------|
| 190 | INFLIXIMAB – PCT only – Special Authority see SA20822050<br>(amended restriction criteria – amended criteria shown only)  |        |      |            |
|     | Inj 100 mg.....   | 806.00 | 1    | ✓ Remicade |
|     | Inj 1 mg for ECP .....  | 8.29   | 1 mg | ✓ Baxter   |
|     | ▶ SA2082 2050 Special Authority for Subsidy   |        |      |            |
|     | Initial application — (plaque psoriasis) only from a dermatologist or Practitioner on the recommendation of a dermatologist. Approvals valid for 3 months for applications meeting the following criteria:  |        |      |            |
|     | Either:   |        |      |            |
|     | 1. Both:  |        |      |            |
|     | 1.1 Patient has had an initial Special Authority approval for adalimumab, or etanercept or <b>secukinumab</b> for severe chronic plaque psoriasis; and  |        |      |            |
|     | 1.2 Either:   |        |      |            |
|     | 1.2.1 Patient has experienced intolerable side effects from adalimumab, or etanercept or <b>secukinumab</b> ; or  |        |      |            |
|     | 1.2.2 Patient has received insufficient benefit from adalimumab, or etanercept or <b>secukinumab</b> to meet the renewal criteria for adalimumab, or etanercept or <b>secukinumab</b> for severe chronic plaque psoriasis; or   |        |      |            |
|     | 2. All of the following:  |        |      |            |
|     | 2.1 Either:   |        |      |            |
|     | 2.1.1 Patient has “whole body” severe chronic plaque psoriasis with a Psoriasis Area and Severity Index (PASI) score of greater than 10, where lesions have been present for at least 6 months from the time of initial diagnosis; or                                   |        |      |            |
|     | 2.1.2 Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and   |        |      |            |
|     | 2.2 Patient has tried, but had an inadequate response (see Notes) to, or has experienced intolerable side effects, from at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, ciclosporin, or acitretin; and |        |      |            |
|     | 2.3 A PASI assessment has been completed for at least the most recent prior treatment course (but preferably all prior treatment courses), preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and       |        |      |            |
|     | 2.4 The most recent PASI assessment is no more than 1 month old at the time of initiation.  |        |      |            |

Note: “Inadequate response” is defined as: for whole body severe chronic plaque psoriasis, a PASI score of greater than 10, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment; for severe chronic plaque psoriasis of the face, hand or foot, at least 2 of the 3 PASI symptom subscores for erythema, thickness and scaling are rated as severe or very severe, and the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment.

Check your Schedule for full details  
Schedule page ref

Subsidy  
(Mnfr's price)  
\$ Per

Brand or  
Generic Mnfr  
✓ fully subsidised

## Changes to Restrictions – effective 1 November 2021 (continued)

204 RITUXIMAB (RIXIMYO) – PCT only – Specialist – Special Authority see SA20832061  
(amended restriction criteria – new criteria shown only)

|                                 |        |      |                    |
|---------------------------------|--------|------|--------------------|
| Inj 100 mg per 10 ml vial ..... | 275.33 | 2    | ✓ Riximyo          |
| Inj 500 mg per 50 ml vial ..... | 688.20 | 1    | ✓ Riximyo          |
| Inj 1 mg for ECP .....          | 1.38   | 1 mg | ✓ Baxter (Riximyo) |

➡ SA2083 2061 Special Authority for Subsidy

**Initial application — (desensitisation prior to transplant) from any relevant practitioner. Approvals valid for 6 weeks for applications meeting the following criteria:**

**Both:**

- 1 Patient requires desensitisation prior to mismatched allogenic stem cell transplant\*; and
- 2 Patient would receive no more than two doses at 375 mg/m<sup>2</sup> of body-surface area.

**Note: Indications marked with \* are unapproved indications.**

214 SECUKINUMAB – Special Authority see SA20842044 – Retail pharmacy  
(amended restriction criteria – amended criteria shown only)

|  |          |   |            |
|--|----------|---|------------|
| Inj 150 mg per ml, 1 ml pre-filled syringe ..... | 799.50   | 1 | ✓ Cosentyx |
|  | 1,599.00 | 2 | ✓ Cosentyx |

➡ SA2084 2044 Special Authority for Subsidy

**Initial application — (psoriatic arthritis) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:**

**Either:**

1 Both:

- 1.1 Patient has had an initial Special Authority approval for adalimumab, or etanercept or infliximab for psoriatic arthritis; and

1.2 Either:

- 1.2.1 Patient has experienced intolerable side effects from adalimumab, or etanercept or infliximab; or
- 1.2.2 Patient has received insufficient benefit from adalimumab, or etanercept or infliximab to meet the renewal criteria for adalimumab, or etanercept or infliximab for psoriatic arthritis; or

2 All of the following:

- 2.1 Patient has had severe active psoriatic arthritis for six months duration or longer; and
- 2.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
- 2.3 Patient has tried and not responded to at least three months of sulfasalazine at a dose of at least 2 g per day or leflunomide at a dose of up to 20 mg daily (or maximum tolerated doses); and
- 2.4 Either:
  - 2.4.1 Patient has persistent symptoms of poorly controlled and active disease in at least 15 swollen, tender joints; or
  - 2.4.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
- 2.5 Any of the following:
  - 2.5.1 Patient has C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
  - 2.5.2 Patient has an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or
  - 2.5.3 ESR and CRP not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist

\* Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details  
Schedule page ref

Subsidy  
(Mnfr's price)  
\$ Per

Brand or  
Generic Mnfr  
✓ fully subsidised

## Changes to Subsidy and Manufacturer's Price

Effective 1 November 2021

|     |  |                |                            |   |
|-----|--|----------------|----------------------------|---|
| 67  | ZINC AND CASTOR OIL († subsidy)<br>* Oint.....   | 4.65           | 500 g                      | ✓ Boucher   |
| 96  | GENTAMICIN SULPHATE († subsidy)<br>Inj 10 mg per ml, 1 ml ampoule – Subsidy by endorsement.....<br>Only if prescribed for a dialysis or cystic fibrosis patient or complicated urinary tract infection and the prescription is endorsed accordingly. | 95.00          | 5                          | ✓ DBL Gentamicin  |
| 112 | IBUPROFEN († subsidy)<br>* Oral liq 20 mg per ml .....   | 2.25           | 200 ml                     | ✓ Ethics  |
| 125 | FENTANYL († subsidy)<br>a) Only on a controlled drug form<br>b) No patient co-payment payable<br>c) Safety medicine; prescriber may determine dispensing frequency<br>Inj 50 mcg per ml, 2 ml ampoule.....   | 3.75           | 10                         | ✓ Boucher and Muir  |
| 132 | PRIMIDONE († subsidy)<br>* Tab 250 mg.....   | 37.35          | 100                        | ✓ Apo-Primidone   |
| 141 | PHENOBARBITONE SODIUM – Special Authority see SA1386 – Retail pharmacy († subsidy)<br>Inj 200 mg per ml, 1 ml ampoule .....  | 103.30         | 10                         | ✓ Max Health <span style="border: 1px solid black; border-radius: 50%; padding: 2px;">S29</span>    |
| 146 | RIVASTIGMINE – Special Authority see SA1488 – Retail pharmacy (↓ subsidy)<br>Patch 9.5 mg per 24 hour .....  | 35.00          | 30                         | ✓ Generic Partners  |
| 171 | OCTREOTIDE († subsidy)<br>Inj 500 mcg per ml, 1 ml ampoule.....  | 113.10         | 5                          | ✓ Octreotide GH <span style="border: 1px solid black; border-radius: 50%; padding: 2px;">S29</span> |
| 226 | BECLOMETHASONE DIPROPIONATE († subsidy)<br>Aerosol inhaler, 50 mcg per dose.....<br>Aerosol inhaler, 100 mcg per dose.....   | 14.01<br>17.52 | 200 dose OP<br>200 dose OP | ✓ Qvar<br>✓ Qvar  |
| 237 | BIMATOPROST († subsidy)<br>* Eye drops 0.03% .....   | 5.95           | 3 ml OP                    | ✓ Bimatoprost<br>Multichem  |



Check your Schedule for full details  
Schedule page ref

Subsidy  
(Mnfr's price)  
\$

Per

Brand or  
Generic Mnfr  
✓ fully subsidised

## Delisted Items

Effective 1 November 2021

|     |  |             |  |
|-----|--|-------------|--|
| 7   | MESALAZINE<br>Suppos 1 g.....54.60   | 30          | ✓ Pentasa  |
|     | Note – this delist is for Pharmacode 2432218   |             |  |
| 23  | INSULIN PUMP INFUSION SET (STEEL CANNULA, STRAIGHT INSERTION)<br>– Special Authority see SA1985 – Retail pharmacy<br>a) Maximum of 3 sets per prescription<br>b) Only on a prescription<br>c) Maximum of 13 infusion sets will be funded per year.<br>6 mm steel cannula; straight insertion; 81 cm line × 10<br>with 10 needles.....130.00  | 1 OP        | ✓ TruSteel   |
|     | 8 mm steel cannula; straight insertion; 81 cm line × 10<br>with 10 needles.....130.00  | 1 OP        | ✓ TruSteel   |
| 44  | FACTOR EIGHT INHIBITOR BYPASSING FRACTION – [Xpharm]<br>For patients with haemophilia. Preferred Brand of bypassing agent for > 14 days predicted use. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.<br>Inj 500 U.....1,315.00  | 1           | ✓ FEIBA NF   |
|     | Note – this delist is for Pharmacode 2388790   |             |  |
| 49  | POTASSIUM CHLORIDE<br>* Inj 75 mg per ml, 10 ml.....55.00  | 50          | ✓ AstraZeneca<br>✓ Potassium Chloride<br>Aguettant <b>\$29</b> |
| 77  | ETHINYLOESTRADIOL WITH DESOGESTREL<br>* Tab 30 mcg with desogestrel 150 mcg and 7 inert tab.....6.62<br>(19.80)  | 84          | Marvelon 28  |
|     | a) Higher subsidy of \$13.80 per 84 tab with Special Authority see SA0500<br>b) Up to 84 tab available on a PSO  |             |  |
| 161 | VINBLASTINE SULPHATE<br>Inj 1 mg per ml, 10 ml vial – PCT<br>– Retail pharmacy-Specialist.....270.37   | 5           | ✓ DBL Vinblastine <b>\$29</b>                                  |
| 231 | SODIUM CROMOGLICATE – Subsidy by endorsement<br>Subsidy by endorsement – Subsidised for patients who were taking sodium cromoglicate prior to 1 July 2020 and the prescription is endorsed accordingly. Pharmacists may annotate the prescription as endorsed where there exists a record of prior dispensing of sodium cromoglicate.<br>Aerosol inhaler, 5 mg per dose CFC-free.....28.07 | 112 dose OP | ✓ Intal Forte CFC Free   |
| 236 | KETOROLAC TROMETAMOL – Special Authority see SA1981 – Retail pharmacy<br>Eye drops 0.5%.....9.50   | 5 ml OP     | ✓ Acular   |
|     | Note – delist delayed to 1 February 2022.  |             |  |
| 236 | NEPAFENAG<br>Eye drops 0.3%.....13.80  | 3 ml OP     | ✓ Ilevro   |
|     | Note – delist delayed to 1 February 2022.  |             |  |

▲ Three months supply may be dispensed at one time if endorsed  
“certified exemption” by the prescriber or pharmacist

\* Three months or six months, as  
applicable, dispensed all-at-once

Check your Schedule for full details  
Schedule page ref

Subsidy  
(Mnfr's price)  
\$ Per

Brand or  
Generic Mnfr  
✓ fully subsidised

## Items to be Delisted

### Effective 1 December 2021

|     |  |       |    |   |                          |
|-----|--|-------|----|---|--------------------------|
| 126 | PARACETAMOL  |       |    |   |                          |
|     | Tab 500 mg - blister pack.....   | 11.75 | 96 | ✓ | <b>Panadol Mini Caps</b> |
|     | a) Maximum of 300 tab per prescription; can be waived by endorsement   |       |    |   |                          |
|     | b) Up to 30 tab available on a PSO   |       |    |   |                          |
|     | c)   |       |    |   |                          |
|     | 1) Subsidy by endorsement for higher quantities is available for patients with long term conditions who require regular daily dosing for one month or greater, and the prescription is annotated accordingly. Pharmacists may annotate the prescription as endorsed where dispensing history supports a long-term condition. |       |    |   |                          |
|     | 2) Maximum of 100 tab per dispensing for non-endorsed patients. If quantities prescribed for more than 100 tabs (for non-endorsed patients), then dispense in repeat dispensings not exceeding 100 tab per dispensing.   |       |    |   |                          |
|     | Note – Panadol Mini Caps tab 500 mg – blister pack delist brought forward from 1 February 2022.  |       |    |   |                          |

### Effective 1 February 2022

|     |  |       |    |   |                          |
|-----|--|-------|----|---|--------------------------|
| 126 | PARACETAMOL  |       |    |   |                          |
|     | Tab 500 mg - blister pack.....   | 11.75 | 96 | ✓ | <b>Panadol Mini Caps</b> |
|     | a) Maximum of 300 tab per prescription; can be waived by endorsement   |       |    |   |                          |
|     | b) Up to 30 tab available on a PSO   |       |    |   |                          |
|     | e)   |       |    |   |                          |
|     | 1) Subsidy by endorsement for higher quantities is available for patients with long term conditions who require regular daily dosing for one month or greater, and the prescription is annotated accordingly. Pharmacists may annotate the prescription as endorsed where dispensing history supports a long-term condition. |       |    |   |                          |
|     | 2) Maximum of 100 tab per dispensing for non-endorsed patients. If quantities prescribed for more than 100 tabs (for non-endorsed patients), then dispense in repeat dispensings not exceeding 100 tab per dispensing.   |       |    |   |                          |
|     | Note – Panadol Mini Caps tab 500 mg – blister pack delist brought forward to 1 December 2021.  |       |    |   |                          |

|     |   |      |         |   |               |
|-----|---|------|---------|---|---------------|
| 236 | KETOROLAC TROMETAMOL – Special Authority see SA1981 – Retail pharmacy |      |         |   |               |
|     | Eye drops 0.5% .....  | 9.50 | 5 ml OP | ✓ | <b>Acular</b> |
|     | Note – this delist is delayed from 1 November 2021.                   |      |         |   |               |

|     |   |       |         |   |               |
|-----|---|-------|---------|---|---------------|
| 236 | NEPAFENAC   |       |         |   |               |
|     | Eye drops 0.3% .....                                | 13.80 | 3 ml OP | ✓ | <b>Ilevro</b> |
|     | Note – this delist is delayed from 1 November 2021. |       |         |   |               |

### Effective 1 April 2022

|    |   |        |       |   |  |
|----|---|--------|-------|---|--|
| 66 | AQUEOUS CREAM   |        |       |   |  |
|    | * Crm.....  | 1.92   | 500 g | ✓ | <b>Basic AquaCream</b><br><b>Boucher</b><br><b>Medco</b> |
| 79 | CINACALCET – Special Authority see SA1618 – Retail pharmacy |        |       |   |  |
|    | Tab 30 mg – Wastage claimable.....                          | 210.30 | 28    | ✓ | <b>Sensipar</b>  |

| Check your Schedule for full details<br>Schedule page ref | Subsidy<br>(Mnfr's price)<br>\$ | Per | Brand or<br>Generic Mnfr<br>✓ fully subsidised |
|---|---------------------------------|-----|--|
|---|---------------------------------|-----|--|

### Items to be Delisted – effective 1 April 2021 (continued)

|     |   |       |     |                             |
|-----|---|-------|-----|-----------------------------|
| 120 | ENTACAPONE<br>▲ Tab 200 mg.....   | 22.00 | 100 | ✓ Entapone                  |
| 122 | SELEGILINE HYDROCHLORIDE – Subsidy by endorsement<br>Subsidy by endorsement – Subsidised for patients who were taking selegiline hydrochloride prior to 1 August 2021 and the prescription is endorsed accordingly. Pharmacists may annotate the prescription as endorsed where there exists a record of prior dispensing of selegiline hydrochloride.<br>* Tab 5 mg..... | 22.00 | 100 | ✓ Apo-Selegiline S29<br>S29 |
| 140 | MELATONIN – Special Authority see SA1666 – Retail pharmacy<br>Tab modified-release 2 mg – No more than 5 tab per day.....   | 28.22 | 30  | ✓ Circadin                  |

### Effective 1 May 2022

|    |  |                               |                     |  |
|----|--|-------------------------------|---------------------|--|
| 34 | PYRIDOXINE HYDROCHLORIDE<br>a) No more than 100 mg per dose<br>b) Only on a prescription<br>Tab 50 mg.....   | 13.63                         | 500                 | ✓ Apo-Pyridoxine   |
| 39 | FOLIC ACID<br>Tab 0.8 mg.....  | 21.84                         | 1,000               | ✓ Apo-Folic Acid   |
| 63 | CICLOPIROX OLAMINE<br>a) Only on a prescription<br>b) Not in combination<br>Nail-soln 8%.....  | 5.72                          | 7 ml OP             | ✓ Apo-Ciclopirox   |
| 77 | OXYBUTYNIN – Subsidy by endorsement<br>Subsidy by endorsement – Subsidised for patients who were taking oxybutynin prior to 1 June 2021 and the prescription is endorsed accordingly. Pharmacists may annotate the prescription as endorsed where there exists a record of prior dispensing of oxybutynin.<br>* Tab 5 mg.....    | 11.70                         | 500                 | ✓ Apo-Oxybutynin   |
| 83 | OESTRADIOL – See prescribing guideline<br>Patch 25 mcg per day.....<br>a) No more than 2 patch per week<br>b) Only on a prescription<br>Patch 50 mcg per day.....<br>a) No more than 2 patch per week<br>b) Only on a prescription<br>Patch 75 mcg per day.....<br>a) No more than 2 patch per week<br>b) Only on a prescription | 7.85<br><br>9.22<br><br>10.60 | 8<br><br>8<br><br>8 | ✓ Estradiol TDP<br>Mylan S29<br><br>✓ Estradiol TDP<br>Mylan S29<br><br>✓ Estradiol TDP<br>Mylan S29 |

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist

\* Three months or six months, as applicable, dispensed all-at-once

# Index

## Pharmaceuticals and brands

|   |        |  |
|---|--------|--|
| <b>A</b>  |        |  |
| Acular .....  | 25, 26 |  |
| Amisulpride.....  | 19     |  |
| Apo-Ciclopirox .....  | 27     |  |
| Apo-Clarithromycin .....  | 21     |  |
| Apo-Folic Acid .....  | 27     |  |
| Apo-Oxybutynin .....  | 27     |  |
| Apo-Prazosin .....  | 21     |  |
| Apo-Prazosin S29 .....  | 19, 21 |  |
| Apo-Primidone .....   | 24     |  |
| Apo-Pyridoxine .....  | 27     |  |
| Apo-Selegiline S29.....   | 27     |  |
| Aqueous cream.....  | 19, 26 |  |
| <b>B</b>  |        |  |
| Basic AquaCream .....   | 26     |  |
| Baxter (Riximyo) .....  | 23     |  |
| Beclomethasone dipropionate.....                                      | 24     |  |
| Bimatoprost .....   | 24     |  |
| Bimatoprost Multichem .....   | 24     |  |
| Bortezomib .....  | 20     |  |
| Bortezomib Dr Reddy's S29 .....                                       | 20     |  |
| Bortezomib Juno .....   | 20     |  |
| <b>C</b>  |        |  |
| Ciclopirox olamine.....   | 27     |  |
| Cinacalcet .....  | 19, 26 |  |
| Cinacalcet Devatis.....   | 19     |  |
| Circadin .....  | 27     |  |
| Clarithromycin.....   | 21     |  |
| Comtan.....   | 19     |  |
| Cosentyx.....   | 23     |  |
| <b>D</b>  |        |  |
| Darunavir .....   | 19     |  |
| Darunavir Mylan.....  | 19     |  |
| DBL Gentamicin .....  | 24     |  |
| DBL Vinblastine.....  | 25     |  |
| <b>E</b>  |        |  |
| Entacapone.....   | 19, 27 |  |
| Entapone .....  | 27     |  |
| Estradiol TDP Mylan .....   | 27     |  |
| Ethinylloestradiol with desogestrel.....                              | 25     |  |
| <b>F</b>  |        |  |
| Factor eight inhibitor bypassing fraction.....                        | 25     |  |
| FEIBA NF.....   | 25     |  |
| Fentanyl.....   | 24     |  |
| Folic acid .....  | 19, 27 |  |
| Folic Acid multichem .....  | 19     |  |
| <b>G</b>  |        |  |
| GEM Aqueous Cream .....   | 19     |  |
| Gentamicin sulphate .....   | 24     |  |
| <b>I</b>  |        |  |
| Ibuprofen .....   | 24     |  |
| Illevro .....   | 25, 26 |  |
| Infliximab .....  | 22     |  |
| Insulin pump infusion set<br>(steel cannula, straight insertion)..... | 25     |  |
| Intal Forte CFC Free .....  | 25     |  |
| <b>K</b>  |        |  |
| Ketoconazole .....  | 19     |  |
| Ketorolac trometamol.....   | 25, 26 |  |
| Klacid .....  | 21     |  |
| <b>M</b>  |        |  |
| Marvelon 28.....  | 25     |  |
| Melatonin .....   | 19, 27 |  |
| Mesalazine.....   | 25     |  |
| Methyldopa .....  | 19     |  |
| Methyldopa Mylan.....   | 19     |  |
| <b>N</b>  |        |  |
| Nepafenac .....   | 25, 26 |  |
| <b>O</b>  |        |  |
| Octreotide .....  | 24     |  |
| Octreotide GH .....   | 24     |  |
| Oestradiol .....  | 27     |  |
| Oestradiol valerate.....  | 21     |  |
| Oxybutynin.....   | 27     |  |
| <b>P</b>  |        |  |
| Panadol Mini Caps .....   | 26     |  |
| Paracetamol.....  | 26     |  |
| Pentasa .....   | 25     |  |
| Phenobarbitone sodium.....  | 24     |  |
| Potassium chloride .....  | 25     |  |
| Potassium Chloride Aguettant.....                                     | 25     |  |
| Prazosin.....   | 19, 21 |  |
| Primidone .....   | 24     |  |
| Progynova .....   | 21     |  |
| Pyridoxine hydrochloride .....  | 19, 27 |  |
| Pyridoxine multichem .....  | 19     |  |
| <b>Q</b>  |        |  |
| Qvar.....   | 24     |  |
| <b>R</b>  |        |  |
| Remicade .....  | 22     |  |
| Rituximab (Riximyo).....  | 23     |  |
| Rivastigmine .....  | 24     |  |
| Riximyo .....   | 23     |  |
| <b>S</b>  |        |  |
| Sebizole.....   | 19     |  |
| Secukinumab .....   | 23     |  |
| Selegiline hydrochloride .....  | 27     |  |
| Sensipar .....  | 26     |  |
| Sodium cromoglicate .....   | 25     |  |
| Sulprix .....   | 19     |  |
| <b>T</b>  |        |  |
| Testosterone undecanoate.....   | 21     |  |

# Index

## Pharmaceuticals and brands

---

|                |    |                            |    |
|----------------|----|----------------------------|----|
| TruSteel ..... | 25 | Vinblastine sulphate ..... | 25 |
| <b>V</b>       |    | <b>Z</b>                   |    |
| Vigisom .....  | 19 | Zinc and castor oil.....   | 24 |

New Zealand  
Permit No. 478



Pharmaceutical Management Agency

Level 9, 40 Mercer Street, PO Box 10254, Wellington 6143, New Zealand

Phone: 64 4 460 4990 - Fax: 64 4 460 4995 - [www.pharmac.govt.nz](http://www.pharmac.govt.nz)

Email: [enquiry@pharmac.govt.nz](mailto:enquiry@pharmac.govt.nz)

ISSN 1172-9376 (Print)

ISSN 1179-3686 (Online)

Te Kāwanatanga o [Aotearoa](#) [New Zealand](#) Government

While care has been taken in compiling this Update, Pharmaceutical Management Agency takes no responsibility for any errors or omissions and shall not be liable to any person for any damages or loss arising out of reliance by that person for any purpose on any of the contents of this Update. Errors and omissions brought to the attention of Pharmaceutical Management Agency will be corrected if necessary by an erratum or otherwise in the next edition of the update.

If Undelivered, Return To: PO Box 10254, Wellington 6143, New Zealand